TW200824707A - Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases - Google Patents

Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases Download PDF

Info

Publication number
TW200824707A
TW200824707A TW096139048A TW96139048A TW200824707A TW 200824707 A TW200824707 A TW 200824707A TW 096139048 A TW096139048 A TW 096139048A TW 96139048 A TW96139048 A TW 96139048A TW 200824707 A TW200824707 A TW 200824707A
Authority
TW
Taiwan
Prior art keywords
antibody
gly
cys
seq
ala
Prior art date
Application number
TW096139048A
Other languages
English (en)
Chinese (zh)
Inventor
Kang Li
Bin-Bing Stephen Zhou
Wen-Juan Wu
Sek Chung Fung
Sanjaya Singh
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TW200824707A publication Critical patent/TW200824707A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
TW096139048A 2006-10-19 2007-10-18 Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases TW200824707A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85286106P 2006-10-19 2006-10-19
US87921807P 2007-01-06 2007-01-06

Publications (1)

Publication Number Publication Date
TW200824707A true TW200824707A (en) 2008-06-16

Family

ID=39325263

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096139048A TW200824707A (en) 2006-10-19 2007-10-18 Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases

Country Status (19)

Country Link
US (5) US7915390B2 (2)
EP (1) EP2087006B1 (2)
JP (1) JP5478254B2 (2)
KR (2) KR20150023953A (2)
AR (1) AR063494A1 (2)
AU (1) AU2007309229B8 (2)
BR (1) BRPI0715989A8 (2)
CA (1) CA2666672A1 (2)
CL (1) CL2007002987A1 (2)
CO (1) CO6180445A2 (2)
CR (1) CR10730A (2)
MA (1) MA30900B1 (2)
MX (1) MX2009004106A (2)
NO (1) NO20091926L (2)
PE (1) PE20081264A1 (2)
PH (1) PH12015500576A1 (2)
RU (1) RU2461569C2 (2)
TW (1) TW200824707A (2)
WO (1) WO2008051797A2 (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
AR063494A1 (es) * 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
JP5386364B2 (ja) * 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
EP2125887A4 (en) 2007-01-24 2010-11-10 Oncomed Pharm Inc COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008100563A2 (en) * 2007-02-14 2008-08-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
MX2010002053A (es) 2007-08-23 2010-07-28 Univ Columbia Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JP2012500791A (ja) 2008-08-22 2012-01-12 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｎｏｔｃｈ３シグナル伝達のデコイインヒビターとしてのヒトｎｏｔｃｈ３に基づく融合タンパク質
PE20120080A1 (es) * 2008-10-01 2012-02-17 Genentech Inc Anticuerpos anti-notch2 y metodos de uso
WO2010141249A2 (en) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
JP5113812B2 (ja) * 2009-08-31 2013-01-09 清 中川 コロニーピッキング装置、コロニーピッキング方法、及び融合細胞クローン作製方法
CA2775880A1 (en) 2009-09-30 2011-04-07 Genentech, Inc. Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
US20130095493A1 (en) * 2011-10-03 2013-04-18 The Johns Hopkins University Identification of the gene notch3 as a novel biomarker for human metastatic melanoma
TW201329105A (zh) 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
US20150140043A1 (en) * 2012-05-10 2015-05-21 Institut National De La Sante De La Recherche Medical (Inserm) Immunomodulatory methods using notch agonists
HK1214282A1 (zh) * 2012-11-07 2016-07-22 辉瑞公司 抗-notch3抗体及抗体-药物缀合物
WO2014100435A1 (en) * 2012-12-19 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-notch3 antibodies
EP2970479B1 (en) 2013-03-14 2019-04-24 Novartis AG Antibodies against notch 3
US9683039B2 (en) * 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
BR112016028537A2 (pt) * 2014-06-04 2017-08-22 Hutchinson Fred Cancer Res expansão e enxerto de células-tronco utilizando agonistas de notch 1 e/ou de notch 2
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
US10407500B2 (en) 2014-09-25 2019-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immunological treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
PE20190126A1 (es) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
DK3448420T3 (da) * 2016-04-29 2022-12-12 Aveo Pharmaceuticals Inc Anti-notch3-antistof
WO2018183216A1 (en) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Notch3 agonist compositions and methods for treating small vessel diseases
US20200103419A1 (en) 2017-03-27 2020-04-02 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
CA3074126A1 (en) * 2017-08-29 2019-03-07 Veritas Therapeutics Inc. Fgl2 antibodies and binding fragments thereof and uses thereof
BR112021003830A2 (pt) 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
US12269874B2 (en) * 2018-12-03 2025-04-08 mAbProtein Co., Ltd. Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
US20230383011A1 (en) * 2020-06-30 2023-11-30 Chugai Seiyaku Kabushiki Kaisha Site specific notch-activating molecule and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6436650B1 (en) * 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
FR2777285B1 (fr) 1998-04-10 2000-05-19 Bio Merieux Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
AU2001288628A1 (en) * 2000-08-31 2002-03-13 Loyola University Chicago Method and reagents for treatment of skin disorders by modulating the notch pathway
JP4365583B2 (ja) 2000-09-22 2009-11-18 ジェネンテック・インコーポレーテッド ノッチレセプターアゴニスト及び用途
WO2004013179A1 (en) * 2002-08-03 2004-02-12 Lorantis Limited Conjugate of notch signalling pathway modulators and their use in medical treatment
US7837993B2 (en) 2004-03-19 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regeneration of aged skeletal muscle tissues
AU2005271892A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
DK1962895T3 (da) * 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
AR063494A1 (es) * 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
JP5386364B2 (ja) * 2006-12-18 2014-01-15 ジェネンテック， インコーポレイテッド 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica

Also Published As

Publication number Publication date
US7994285B2 (en) 2011-08-09
US20080131908A1 (en) 2008-06-05
CR10730A (es) 2009-06-19
RU2009118621A (ru) 2010-11-27
KR20150023953A (ko) 2015-03-05
EP2087006A2 (en) 2009-08-12
MX2009004106A (es) 2009-04-28
WO2008051797A3 (en) 2008-07-31
PE20081264A1 (es) 2008-10-01
RU2461569C2 (ru) 2012-09-20
AR063494A1 (es) 2009-01-28
AU2007309229B2 (en) 2013-01-10
US9518124B2 (en) 2016-12-13
AU2007309229A2 (en) 2009-05-28
JP5478254B2 (ja) 2014-04-23
EP2087006B1 (en) 2016-06-08
NO20091926L (no) 2009-07-17
US20110206675A1 (en) 2011-08-25
PH12015500576A1 (en) 2016-07-25
CL2007002987A1 (es) 2008-06-06
CA2666672A1 (en) 2008-05-02
US20120213785A1 (en) 2012-08-23
JP2010506596A (ja) 2010-03-04
AU2007309229A1 (en) 2008-05-02
CO6180445A2 (es) 2010-07-19
US7915390B2 (en) 2011-03-29
AU2007309229B8 (en) 2013-05-09
BRPI0715989A2 (pt) 2014-03-18
US20140093889A1 (en) 2014-04-03
KR101525629B1 (ko) 2015-06-26
BRPI0715989A8 (pt) 2018-03-13
MA30900B1 (fr) 2009-11-02
US20100111971A9 (en) 2010-05-06
US20080118520A1 (en) 2008-05-22
KR20090080979A (ko) 2009-07-27
US8187839B2 (en) 2012-05-29
WO2008051797A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
TW200824707A (en) Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
TWI419904B (zh) 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
CN101563366B (zh) 抗notch3激动性抗体及其在制备治疗notch3相关疾病的药物中的用途
KR20100014588A (ko) 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
CN101605815B (zh) 拮抗性抗刻缺蛋白3抗体及其在预防和治疗刻缺蛋白3相关疾病中的用途
HK1134301B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
IL198079A (en) Anti-3 Notch Agonist Antibodies and Their Use in Preparing Drugs for the Treatment of 3 Notch
HK1134300B (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases